Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298576 | 0.88 | NAMPT (0.61) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3407377 | 0.84 | FAAH (0.43) | NAMPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL8093604 | 0.81 | NAMPT (0.54) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2294218 | 0.81 | NAMPT (0.51) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2297342 | 0.80 | SCD (0.55) | NAMPT | |
| SCHEMBL3408635 | 0.80 | NAMPT (0.50) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2290893 | 0.79 | NAMPT (0.53) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2290030 | 0.76 | HDAC3 (0.46) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8093277 | 0.76 | NAMPT (0.47) | NAMPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2295194 | 0.76 | NAMPT (0.47) | NAMPTHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| EP-2152711-B1 | 2 -HETEROARYL- PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI AVENTIS (FR) | 2010-11-24 | — | — | EP | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008135141-A1 | 2 -HETEROARYL- PYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SCD, SCD5, PYCR1 | NAMPT 1406/4885HDAC3 3488/4885HDAC4 4531/4885 |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SCD, SCD5, PYCR1 | NAMPT 1694/4885HDAC3 3350/4885HDAC4 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.